Zhejiang Boxiao Biopharmaceutical

Zhejiang Boxiao Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), as well as oncology and inflammatory disorders. Its lead candidate, BX001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist designed to treat NASH and hyperlipidemia while minimizing off-target effects associated with the alpha receptor. Boxiao leverages its internal R&D capabilities to advance a pipeline of high-potential assets through clinical development. The company is supported by prominent venture capital investors, including HighLight Capital and Qiming Venture Partners. By addressing significant unmet medical needs in chronic metabolic conditions, Boxiao aims to provide effective and safe treatment options for patients globally.